Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...
WAUSAU, Wis. (WSAW) - In the past, being diagnosed with small-cell lung cancer seemed to be a death sentence. This type of cancer is known as one of the most aggressive and deadliest forms of cancer.
Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
Yale researchers recently discovered new genes that could be used to test potential treatment options for a rare form of aggressive lung cancer. Each year, about 6,000 Americans — roughly 3 percent of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...
Please provide your email address to receive an email when new articles are posted on . New treatments for lung cancer and melanoma have significantly improved OS, but also have exacerbated ...
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...